abstract |
The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of receptor 1 of the transforming growth factor beta (TGFβR1), pharmaceutical compositions comprising the compounds and methods for using the compounds for treating cancer, preferably colon cancer, melanoma, Hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer and gastric cancer and / or fibrosis, preferably liver fibrosis and chronic kidney disease. |